STK11 and non-small cell lung carcinoma: On the basis of these data, we aimed to determine if concomitant LKB1 mutation in KRAS-mutant NSCLC directly associates with decreased response to MEK inhibitor selumetinib, and if so, to define the underlying mechanism.